ライフサイエンスコーパス: interleukin-4

1 CD154, as well as by lipopolysaccharide and interleukin 4.

2 n children who survived, and lower levels of interleukin 4.

3 x vivo with a combination of CD40 ligand and interleukin 4.

4 tic cytokines interferon, interleukin-2, and interleukin-4.

5 oduced more gamma interferon (IFN-gamma) and interleukin-4.

6 requires GITR, CD4(+) T cells, B cells, and interleukin-4.

7 M)-CSF-dependent manner but independently of interleukin-4.

8 type on CD8(+) T cells through production of interleukin-4.

9 ced significant increases in serum levels of interleukin-4.

10 cyte-macrophage colony-stimulating factor or interleukin-4.

11 cells by the quintessential type 2 cytokine, interleukin-4.

12 to release the immunomodulatory key cytokine interleukin-4.

13 tumor necrosis factor-alpha (TNF-alpha), and interleukins 4, 10, and 12p70 were determined.

14 phils, 2) serum IgE levels, 3) T2 cytokines (interleukin-4, -13, and -4 to interferon-gamma ratio), a

15 ess syndrome mortality, when increased, were interleukin-4 (18.0 [6.0-54.2]), interleukin-2 (11.8 [4.

16 h2) cells and innate lymphoid cells, such as interleukins 4, 5, and 13, as underlying the eosinophili

17 Gene expression of interleukins 4, 6, and 13, interferon-gamma, tumor necro

18 )-adrenergic receptor (beta(2)AR) on a CD40L/interleukin-4-activated B lymphocyte increases the level

19 hich Arg1 expression is greatly increased by interleukin 4 and 13 signaling through the transcription

20 d children with measles, and lower levels of interleukin 4 and 5.

21 provoked concentrations of interleukin 3 and interleukin 4 and augmented levels of interleukin 12 in

22 NKT cells failed to secrete large amounts of interleukin 4 and interferon-gamma after activation; how

23 table safety, validating the crucial role of interleukin 4 and interleukin 13 in atopic dermatitis pa

24 gE, a product of B cells from the actions of interleukin 4 and interleukin 13, is used as treatment f

25 ha monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines i

26 Conversely, minimal interleukin 4 and interleukin 17 production was detected

27 ers have established unanticipated roles for interleukin 4 and the alternative activation of tissue m

28 pressing accessory cells in media containing interleukin-4 and -10.

29 ith T(FH) cell coexpression of the cytokines interleukin-4 and -21.

30 e immunized with a sopB mutant showed higher interleukin-4 and gamma interferon secretion levels than

31 as associated with increased serum levels of interleukin-4 and immunoglobulins G1 and E directed agai

32 and show substantively lower serum levels of interleukin-4 and interferon-gamma when compared with ma

33 3(+)T-bet(+) cells capable of producing both interleukin-4 and interferon-gamma.

34 r-alpha or interleukin-6 was Int1 dependent; interleukin-4 and interleukin-10 were not detected.

35 wed disease progression, and the addition of interleukin-4 and interleukin-13 blockade with dupilumab

36 TGF-beta signaling also led to a decrease in interleukin-4 and interleukin-13 concentrations, which d

37 receptor alpha monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers

38 f three signaling complexes of the cytokines interleukin-4 and interleukin-13 with their receptors, s

39 fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in

40 tively activated macrophages, polarized with interleukin-4 and interleukin-13.

41 gic testing showed exaggerated production of interleukin-4 and reduced production of interferon-gamma

42 CD300a expression on memory B cells, whereas interleukin-4 and transforming growth factor-beta1 act a

43 her levels of Th-1 (interferon-gamma), Th-2 (interleukin-4), and Th-17 (interleukin-17)-associated cy

44 terferon gamma, tumor necrosis factor alpha, interleukin 4, and interleukin 13 in the liver and splee

45 T cells produced less interferon gamma, interleukin 4, and interleukin 17 upon coculture with B

46 activator interferon gamma, the M2 activator interleukin 4, and M2-associated anti-inflammatory inter

47 nditions blocked up-regulation of GATA-3 and interleukin-4, and in effector/memory CD4(+) T cells, de

48 locyte-macrophage colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha and fused

49 Ibrutinib treatment increased the number of interleukin 4- and interferon gamma-producing natural ki

50 evels of transforming growth factor beta and interleukin 4; and fewer myofibroblast infiltration (den

51 Neutralizing interleukin-4 antibody therapy given only in the newborn

52 sphate-buffered saline challenge, except for interleukin-4 at 9 hrs).

53 The former evoked lower interleukin-4, but higher interferon-gamma, mRNA express

54 ependent on basophils, immunoglobulin E, and interleukin-4, but was independent of mast cells.

55 ing pulmonary inflammation, basophil-derived interleukin-4 can act on lung-infiltrating monocytes cau

56 locyte-macrophage colony-stimulating factor, interleukin-4, CD40L, and interferon-gamma, resulting in

57 ith subsequent assay of interferon-gamma and interleukin 4 cell expression using ELISPOT technique.

58 ization status in C. neoformans-infected WT, interleukin-4-deficient (IL-4(-/-)), and gamma interfero

59 The levels of interferon gamma- and interleukin 4-dependent induction of the cationic amino

60 tor-dependent T helper 2 pathway that guides interleukin-4-dependent macrophage polarization, which i

61 pient invariant natural killer T-cell (iNKT) interleukin-4-driven expansion of donor Foxp3(+) natural

62 fibroblasts] responds to stimuli (bleomycin, interleukin-4, etc) with increased latent transforming g

63 exposed to Hb:haptoglobin complexes, but not interleukin-4, expressed the M(Hb) phenotype and were ch

64 early slowly progressing stages, augmenting interleukin-4 expression and protective M2 microglia, an

65 ay be mediated by the augmented secretion of interleukin-4 from mutant Cu2+/Zn2+ superoxide dismutase

66 r levels of mRNAs for PD-1, CD4, CD8, F4/80, interleukin-4, gamma interferon, granzyme A, and granzym

67 Interleukin-4 high (IL-4(hi)) FL-TFH cells, unlike FL B

68 naive T cells into an interferon-gamma(low), interleukin-4(high) and FoxP3(+) immunoregulatory phenot

69 In this context, interleukin 4 (IL-4) and granulocyte macrophage colony-s

70 The Th2 cytokines interleukin 4 (IL-4) and IL-13 and the heterodimeric IL-

71 Interleukin 4 (IL-4) and IL-13 are critical for response

72 responses were retained while nonprotective interleukin 4 (IL-4) and IL-5 were diminished.

73 2,6-sialylated glycoform of IgG Fc to induce Interleukin 4 (IL-4) and Signal Transducer and Activator

74 One such macro PARP, PARP-14 alters interleukin 4 (IL-4) and Stat6-dependent transcription.

75 Foxp3 expression was caused by production of interleukin 4 (IL-4) by Ndfip1(-/-) cells.

76 ansforming growth factor-beta (TGF-beta) and interleukin 4 (IL-4) control the differentiation of CD4(

77 Interleukin 4 (IL-4) drives T(H)2 differentiation and IL

78 (iNKT cells) can produce copious amounts of interleukin 4 (IL-4) early during infection.

79 g cytokines interferon gamma (IFN-gamma) and interleukin 4 (IL-4) in the regulation of mycoplasma-spe

80 Interleukin 4 (IL-4) inhibits receptor activator of NF-k

81 Alternative activation with interleukin 4 (IL-4) normalized CGD macrophage efferocyt

82 ected deer mice, including activation of the interleukin 4 (IL-4) pathway in T cells and B cells.

83 Th2 cytokines such as interleukin 4 (IL-4) polarize macrophages to a state of

84 ic deficiency in KLF2 but instead was due to interleukin 4 (IL-4) produced by an expanded population

85 e show that interferon-gamma (IFN-gamma) and interleukin 4 (IL-4) signaled to the majority of lymphoc

86 Macrophages stimulated by interleukin 4 (IL-4) to become alternatively (or, M2) ac

87 eukin 4 receptor alpha (IL-4Ralpha)(-/-) and interleukin 4 (IL-4)(-/-) BALB/c mice have indicated tha

88 We have focused here on interleukin 4 (IL-4), a cytokine that protects normal an

89 lon and Igamma1 transcription in response to interleukin 4 (IL-4), hence class switching to IgE and I

90 tact-sensitized mice preferentially produced interleukin 4 (IL-4), IL-10, and IL-17; CD8(+) T cells,

91 matory (M2) macrophage activation, including interleukin 4 (IL-4), IL-13, and FIZZ1.

92 Dec2 promoted expression of interleukin 4 (IL-4), IL-5 and IL-13 during early T(H)2

93 tein CIS, which was substantially induced by interleukin 4 (IL-4), negatively regulated the activatio

94 become lodged in the host liver, evoking an interleukin 4 (IL-4)- and IL-13-mediated dominant CD4(+)

95 is required for the phenotypic conversion of interleukin 4 (IL-4)-activated monocyte-derived F4/80(in

96 H1N1-specific interleukin 4 (IL-4)-producing CD4(+) T-cell frequencies

97 xpression and terminally differentiated into interleukin 4 (IL-4)-producing NKT2 cells or IL-17-produ

98 XCL13 were also necessary for development of interleukin 4 (IL-4)-producing type 2 helper T cells (T(

99 ritic cells (DCs) and basophils positive for interleukin 4 (IL-4).

100 ease in the median fluorescence intensity of interleukin 4 (IL-4; P < .05) and interleukin 10 (IL-10;

101 iven via the alpha-chain of the receptor for interleukin 4 (IL-4Ralpha) is important for immunity to

102 ction/luciferase reporter assays, heightened interleukin-4 (IL-4) -induced activation of target genes

103 n monocytes were differentiated into iDCs by interleukin-4 (IL-4) and granulocyte-macrophage colony-s

104 infected BALB/c-CXCR3(Tg) mice produced more interleukin-4 (IL-4) and IL-10 and less gamma interferon

105 later time points, levels of Th2-associated interleukin-4 (IL-4) and IL-10 were also lower in miR155

106 Nematode infection upregulates interleukin-4 (IL-4) and IL-13 and induces STAT6-depende

107 by which the T helper 2 (Th2) cell cytokines interleukin-4 (IL-4) and IL-13 mediate their effects on

108 Interleukin-4 (IL-4) and IL-13 regulate sPLA2 and MUC2 p

109 ifferent class of proinflammatory cytokines, interleukin-4 (IL-4) and IL-13, in the induction of infl

110 aracterized by the induction of the cytokine interleukin-4 (IL-4) and the activation of the transcrip

111 l BEAS-2B cells by proinflammatory cytokines interleukin-4 (IL-4) and tumor necrosis factor alpha (TN

112 the control of the archetypal T(H)2 cytokine interleukin-4 (IL-4) and was a fundamental component of

113 Thymic NKT2 cells that produced interleukin-4 (IL-4) at steady state were located in the

114 We show that exposure to interleukin-4 (IL-4) during DC differentiation enhances

115 hown that the type 2 cell signature cytokine interleukin-4 (IL-4) hampers neutrophil expansion and mi

116 ere we show an increase in the production of interleukin-4 (IL-4) in p38alpha(-/-) CD4(+) T cells in

117 cells (Tfh cells) are the major producers of interleukin-4 (IL-4) in secondary lymphoid organs where

118 Interleukin-4 (IL-4) is crucial in many helminth infecti

119 Although T(FH) cell-derived interleukin-4 (IL-4) is necessary for IgE production, it

120 Interleukin-4 (IL-4) is produced by a unique subset of i

121 Finally, we demonstrate that interleukin-4 (IL-4) is responsible for inducing catheps

122 We further find that interleukin-4 (IL-4) markedly rescues CD79b and sIgM pro

123 that inhibition of Th2 differentiation using interleukin-4 (IL-4) or IL-13 blockade prevents initiati

124 while similar recombinant viruses expressing interleukin-4 (IL-4) or interferon gamma (IFN-gamma) did

125 crophage markers by a mechanism dependent on interleukin-4 (IL-4) or interleukin-13 (IL-13) activatio

126 of activated T cells signaling triggering to interleukin-4 (IL-4) overexpression.

127 The interleukin-4 (IL-4) pathway, which has previously been

128 ation in Socs2(-/-) macrophages and enhanced interleukin-4 (IL-4) plus IL-13-induced STAT6 phosphoryl

129 ligand 2 (CXCL2) and CXCL8, without or with interleukin-4 (IL-4) pre-incubation.

130 der exposure to S. haematobium eggs triggers interleukin-4 (IL-4) production and makes BALB/c mice su

131 Enhanced T-cell-mediated interleukin-4 (IL-4) production promotes the development

132 TMEV-specific lymphoproliferative responses, interleukin-4 (IL-4) production, and IL-4/gamma interfer

133 as partially mediated by CD4+ T cells and by interleukin-4 (IL-4) production, did not require eosinop

134 was associated with exposure, with increased interleukin-4 (IL-4) production, IL-5 transcription, and

135 n (TSLP) and type 2 immunity, in particular, interleukin-4 (IL-4) production, in mediating hepatic eo

136 which each functioned independently to limit interleukin-4 (IL-4) production.

137 ith the ability of IRF4/PU.1 to activate the interleukin-4 (IL-4) promoter, strongly suggesting a rol

138 Here, we report that interleukin-4 (IL-4) promotes oligodendrocyte regenerati

139 -gamma) recall responses rather than reduced interleukin-4 (IL-4) responses, suggesting that immunopa

140 by tumor-associated microglia in response to interleukin-4 (IL-4) stimulation.

141 Interleukin-4 (IL-4) suppresses the development of multi

142 Of the cytokines examined, Ag-specific interleukin-4 (IL-4) T-helper enzyme-linked immunosorben

143 mbinant RSV vectors expressing IFN-gamma and interleukin-4 (IL-4) that allow us to explore the role o

144 ha (TNF-alpha), lipopolysaccharide (LPS), or interleukin-4 (IL-4) to induce classic (M1 and M(LPS)) o

145 We found that continuous interleukin-4 (IL-4) treatment leads to decreased H3K27

146 rates in mice deficient in the Th2 cytokine interleukin-4 (IL-4) via STAT6 mutation in a BALB/c back

147 Whereas interleukin-4 (IL-4) was dispensable for papain-induced

148 Concentration of type-2 cytokine interleukin-4 (IL-4) was significantly less in both grou

149 nd gamma interferon (LPS/IFN-gamma) and with interleukin-4 (IL-4) were used as controls.

150 n NKT-cell-deficient Jalpha18(-/-) hosts and interleukin-4 (IL-4)(-/-) hosts, or when the donor trans

151 thal ischemia, local neurons rapidly produce interleukin-4 (IL-4), a cytokine with potent anti-inflam

152 reduced levels of ileal transcripts encoding interleukin-4 (IL-4), a key mediator of intestinal masto

153 production of interferon-gamma (IFN-gamma), interleukin-4 (IL-4), and IL-17.

154 r expansion is driven by the type 2 cytokine interleukin-4 (IL-4), as well as by M-CSF, which also co

155 orylation downstream of RIG-I, IFN-beta, and interleukin-4 (IL-4), but not granulocyte-macrophage col

156 onse is dependent on the T helper 2 cytokine interleukin-4 (IL-4), but not the T helper 1 cytokine in

157 phage-colony stimulating factor (GM-CSF) and interleukin-4 (IL-4), express functional NK1R.

158 Interleukin-4 (IL-4), IL-10, and IL-13 expression and th

159 ited increased production of CD4(+)-specific interleukin-4 (IL-4), IL-5, and IL-13 and CD4(+)Foxp3(+)

160 s of type II immunity, such as production of interleukin-4 (IL-4), IL-5, and IL-13 by whole-lung cell

161 n airway type 2 cytokine activity, including interleukin-4 (IL-4), IL-5, and IL-13, are now establish

162 way disease associated with type 2 cytokines interleukin-4 (IL-4), IL-5, and IL-13, which promote air

163 produce a wide range of cytokines, including interleukin-4 (IL-4), IL-5, IL-13, interferon-gamma, IL-

164 Type 2 inflammatory cytokines, including interleukin-4 (IL-4), IL-5, IL-9, and IL-13, drive the c

165 -type and Th2-promoting cytokines, including interleukin-4 (IL-4), IL-5, IL-9, IL-13, IL-31, and thym

166 pstream stimuli of these pathways, including interleukin-4 (IL-4), IL-6, and IL-13, increased dramati

167 cells was inhibited by even small amounts of interleukin-4 (IL-4), IL-6, and interferon-gamma (IFN-ga

168 onators, the cytokines interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), and tumor ne

169 repair is a subset of a broad repertoire of interleukin-4 (IL-4)- and IL-13-dependent host responses

170 growth factor beta 1 (TGF-beta1) because of interleukin-4 (IL-4)- and signal transducer and activato

171 opment but instead promoted the formation of interleukin-4 (IL-4)-committed T follicular helper (Tfh)

172 e lung, surfactant protein A (SP-A) enhanced interleukin-4 (IL-4)-dependent macrophage proliferation

173 press GVHD caused by 5.0 x 10(5) Tcons in an interleukin-4 (IL-4)-dependent mechanism.

174 Macrophages undergoing interleukin-4 (IL-4)-induced alternative activation in t

175 ped the early and late epigenomic changes of interleukin-4 (IL-4)-induced alternative macrophage pola

176 Recently, we demonstrated that interleukin-4 (IL-4)-induced fusion of mouse macrophages

177 Interleukin-4 (IL-4)-induced T helper (Th) 2 cells promo

178 ly (P </= 0.001) decreased the percentage of interleukin-4 (IL-4)-positive CD4 and CD8 cells in RSV-s

179 ort, we demonstrate that KSHV suppresses the interleukin-4 (IL-4)-stimulated immune response of B-lym

180 rt in mice an unexpected requirement for the interleukin-4 (IL-4)-stimulated program of alternative m

181 h, a process dependent on the T(H)2 cytokine interleukin-4 (IL-4).

182 enesis depended on Dex-induced inhibition of interleukin-4 (IL-4).

183 cell receptor (BCR), CD40 ligand (CD40L), or interleukin-4 (IL-4).

184 phage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4).

185 homeostasis and are induced by the cytokine interleukin-4 (IL-4).

186 oduction of interferon-gamma (IFN-gamma) and interleukin-4 (IL-4).

187 range of cytoprotective cytokines including interleukin-4 (IL-4).

188 ased from CLL cells stimulated with CD40 and interleukin-4 (IL-4).

189 expressed significantly increased levels of interleukin-4 (IL-4).

190 ead secrete a potent M2 polarizing cytokine, interleukin-4 (IL-4).

191 Anti-inflammatory cytokines (interleukin 4 [IL-4] and IL-10) were reported to be abse

192 ulatory/anti-inflammatory cytokine response (interleukin-4 [IL-4] plus IL-10 > tumor necrosis factor

193 nterferon-gamma [IFN-gamma]) yet promoting M(interleukin-4 [IL-4]) effector functions.

194 tors known to generate either alternatively (interleukin-4 [IL-4]) or classically (macrophage colony-

195 ll functions by anti-inflammatory cytokines (interleukin-4 [IL-4], IL-10, and transforming growth fac

196 tes/macrophages, or the levels of cytokines (interleukin-4 [IL-4], IL-10, gamma interferon, or IL-13)

197 y inflammatory cell influx and Th2 cytokine (interleukin-4 [IL-4], IL-5, and IL-13) content relative

198 The anti-inflammatory cytokines (interleukin-4 [IL-4], IL-6, and IL-10) and MCP-1/CCL2 we

199 n protein of the anti-inflammatory cytokines interleukin 4 (IL4) and IL10.

200 ting of two prototypic regulatory cytokines, interleukin 4 (IL4) and IL10.

201 Treatment with ATRA increased interleukin 4 (IL4) and IL12p70 in plasma of infected pi

202 Using sensitive interleukin 4 (Il4) reporter alleles, we demonstrate her

203 d M1 macrophages, but failed to do so in the interleukin 4 (IL4)-induced M2 macrophages.

204 domain, long cytoplasmic tail, 2 (KIR3DL2); interleukin 4 (IL4); and interleukin 13 (IL13).

205 Mo-MLV insertion region 1 homolog (BMI1) and interleukin-4 (IL4) expression, resulting in decreased G

206 The four cytokines erythropoietin (EPO), interleukin-4 (IL4), human growth hormone (hGH), and pro

207 hrough the functionally opposing receptor to interleukin-4 (IL4R).

208 Excessive production of interleukin-4 impairs clearance of the fungal pathogen H

209 had lower expression of interferon-gamma and interleukin 4 in the secondary lymphoid tissues.

210 showed that CD4(+) T cells were a source of interleukin-4 in infected CCR2(-/-) mice, but their cont

211 the data indicate that generation of excess interleukin-4 in lungs of H. capsulatum-infected CCR2(-/

212 CD4+/CD25+/FoxP3+ T lymphocytes co-expressed interleukin-4 in the same cell.

213 Moreover, AR activation upregulated the interleukin-4-induced expression of CCAAT/enhancer-bindi

214 d a positive effect on interferon-gamma- and interleukin-4-induced JAK/STAT activity in HEK293 or HEK

215 Stimulation of B cells with anti-CD40 plus interleukin-4 induces CSR from Cmu to Cgamma1 (IgG1) and

216 reviously showed that a single dose of IPSE (Interleukin-4-inducing principle from Schistosoma eggs),

217 Interleukin-4-inducing principle from schistosome eggs (

218 Conversely, interleukin 4 inhibits the killing of intracellular path

219 alpha) and downregulation of Th2 cytokines (interleukin 4, interleukin 5, interleukin 10, interleuki

220 cytokine production showed higher levels of interleukin-4, interleukin-12, and eotaxin mRNA expressi

221 both in vitro and in vivo, with more robust interleukin-4, interleukin-5, and interleukin-13 product

222 Plasma was assayed for interleukin-1beta, interleukin-4, interleukin-5, interleukin-6, interleukin

223 Level of interleukin-1beta, interleukin-2, interleukin-4, interleukin-5, interleukin-6, interleukin

224 1beta, soluble interleukin-2 receptor-alpha, interleukin-4, interleukin-5, interleukin-7, interleukin

225 Plasma interleukin-1beta, interleukin-4, interleukin-6, interleukin-8, interleukin

226 d significant differences between groups for interleukin-4, interleukin-6, interleukin-9, interleukin

227 Interleukin-4, interleukin-8, granulocyte macrophage col

228 Interleukin-4 is a cytokine widely known for its role in

229 ts of wild-type and cytokine gene-deficient (interleukin-4-knockout [IL-4 (-/-)] and interferon-gamma

230 Interleukin-4, known to be expressed in skin lesions fro

231 f them at the time of infection, reduced the interleukin-4 level in infected CCR2(-/-) mice.

232 An increase in the interleukin-4 level is associated with decreased recruit

233 stantially more immunotherapeutic sustaining interleukin-4 levels and M2 microglia, and resulting in

234 ajor histocompatibility complex class II and interleukin 4 message after helminth infection.

235 acrophage differentiation in the presence of interleukin 4 or dexamethasone.

236 ivation; however, some cells produced either interleukin 4 or interferon-gamma but not both.

237 T cells (P=0.01), and reduced expression of interleukin-4 (P=0.02) in gal-3 null mice suggest possib

238 is directly involved in fusogenic cytokine (interleukin-4 plus granulocyte macrophage-colony stimula

239 Moreover, interleukin-4 polarization lowers expression levels of t

240 In vitro interleukin-4-polarization of human primary monocytes in

241 ietic cell transplantation demonstrated that interleukin-4 polarized human T-Rapa cells had a mixed T

242 that nonpolarized (M0) as well as M1 or M2 (interleukin-4) polarized IPSDM shared transcriptomic pro

243 High levels of interleukin-4-positive (IL-4(+)) and tumor necrosis fact

244 In contrast, Itch(-/-) interleukin-4-producing gammadelta T cells, even in the

245 iNKT cell interleukin 4 production and GC migration were critical

246 of AFV, interferon gamma, interleukin 2, and interleukin 4 production by HBsAg-specific T cells was d

247 ivation, but unlike SEA, it fails to trigger interleukin 4 production from basophils.

248 tigen-specific CD4+ T cell proliferation and interleukin 4 production in vitro, and transfer of basop

249 s following the enhancement of virus-induced interleukin-4 production and subsequent DC-SIGN expressi

250 ction, CD301b(+) DC depletion led to blunted interleukin-4 production by OVA-specific OT-II transgeni

251 n delta-toxin, promoted immunoglobulin-E and interleukin-4 production, as well as inflammatory skin d

252 d the possibility that these cells influence interleukin-4 production.

253 Stimulation of B cells with CD40 ligand and interleukin-4 promoted their ability to transinfect hepa

254 n gamma (IFN-gamma) receptor (IFN-gammaR) or interleukin 4 receptor alpha (IL-4Ralpha) were infected

255 Previous studies comparing interleukin 4 receptor alpha (IL-4Ralpha)(-/-) and inter

256 Focal demyelination in mice lacking IL4I1 or interleukin 4 receptor alpha (IL4Ralpha) results in incr

257 We discuss interleukin 4 receptor pathways, which recently have bee

258 susceptible (Il4ra(F709)) mice with enhanced interleukin-4 receptor (IL-4R) signaling exhibited STAT6

259 s long been established that dimerization of Interleukin-4 receptor (IL-4R) subunits is a pivotal ste

260 ulation of interleukin-1 receptor 1 (IL1r1), interleukin-4 receptor (IL4r), fibroblast growth factor

261 reg) cells in a manner that was dependent on interleukin-4 receptor alpha (IL-4Ralpha) expression in

262 ion, and we demonstrated a role for enhanced interleukin-4 receptor alpha (IL-4Ralpha) expression on

263 ully human monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Ralpha) subunit, demon

264 monstrated that, during skin repair in mice, interleukin-4 receptor alpha (IL-4Ralpha)-dependent macr

265 Polymorphisms in the interleukin-4 receptor alpha chain (IL-4R alpha) have be

266 inical improvement of AD that is mediated by interleukin-4 receptor alpha inhibition and the subseque

267 Dupilumab, a fully human anti-interleukin-4 receptor alpha monoclonal antibody, inhibi

268 Dupilumab is a fully human antibody to interleukin-4 receptor alpha that improves the signs and

269 ) of antibodies that specifically engage the interleukin-4 receptor heterodimer.

270 ensitization, this response was dependent on interleukin-4 receptor signaling.

271 resses the interleukin-1 receptor, CD206 and interleukin-4 receptor, but not CD163.

272 oclonal antibody to the alpha subunit of the interleukin-4 receptor, in patients with persistent, mod

273 inants governing the assembly of the type II interleukin-4 receptor, taking advantage of various agon

274 pressing both miRNAs and a peptide targeting interleukin-4 receptor, which is highly expressed in bre

275 Interleukin-4 receptor-alpha (IL-4Ralpha) mediates the i

276 ergy expenditure in wild-type, Ucp1(-/-) and interleukin-4 receptor-alpha double-negative (Il4ra(-/-)

277 n M2 but not M1 Msmall ef, Cyrillic required interleukin-4 receptor/Stat6.

278 Dupilumab (an anti-interleukin-4-receptor-alpha monoclonal antibody) blocks

279 Dupilumab, an anti-IL (Interleukin) -4 receptoralpha mAb, inhibits IL-4/IL-13 s

280 Using an interleukin 4-reporter system, we show here that CD4(+)

281 (macrophage chemotactic protein-1) and IL-4 (interleukin-4), respectively.

282 -induced ATM infiltration and potentiator of interleukin-4 responses and point toward a crucial role

283 Interleukin 4 reversed the antifungal activity of GM-CSF

284 regulating t-bet gene expression, decreasing interleukin 4 secretion, and downregulating gata3 gene e

285 sor activities through the regulation of the interleukin-4 signaling cascade.

286 ctivated transforming growth factor beta and interleukin-4 signaling in the lesional skin.

287 yte macrophage colony-stimulating factor and interleukin-4 signaling.

288 in human CLL was induced by stimulation with interleukin 4/soluble CD40 ligand and by stroma cell con

289 interleukin 2 (T-helper 1-type cytokine) and interleukin 4 (T-helper 2-type cytokine) in all anti-HBs

290 yte-macrophage colony-stimulating factor and interleukin-4 to generate dendritic cells.

291 erived dendritic cell-mediated regulation of interleukin-4 transcription was dependent on major histo

292 sed gamma interferon secretion and increased interleukin-4 transcription.

293 ngal burden despite the fact that it limited interleukin-4 transcription.

294 cells to infected CCR2(-/-) mice suppressed interleukin-4 transcription.

295 tively activated" M2 macrophages obtained by interleukin 4 treatment, but almost missing in M1 macrop

296 Finally, we showed that interleukin-4 treatment was sufficient to increase the n

297 Upon interleukin-4 treatment, AnxA2 stabilizes the cytosolic

298 kine, GIFT4, engineered by fusing GM-CSF and interleukin-4, was previously found to simulate B cell p

299 e, whereas effects on Th2-cell production of interleukin 4 were more variable.

300 g CTLA4-Ig therapy had lower serum levels of interleukin 4, whereas mice receiving anti-TNF therapy h